Design Therapeutics (DSGN) Enterprise Value (2021 - 2026)

Design Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$207.4 million in Q2 2026.

• Enterprise Value for Q2 2026 came in at -$207.4 million, up 4.11% year-over-year; the trailing twelve-month figure through Jun 2026 was -$207.4 million (up 4.11% YoY), and the FY2025 annual result was -$219.8 million, up 10.44% from the prior year.
• Enterprise Value improved to -$207.4 million in Q2 2026, from -$222.8 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$206.0 million in Q3 2025 and troughed at -$371.2 million in Q1 2022.
• A 5-year average of -$273.9 million and a median of -$265.9 million in 2024 frame the typical range for Enterprise Value.
• The widest annual swing landed in 2025, when Enterprise Value increased 18.93%; it then climbed 2.98% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$330.4 million in 2022, then advanced by 14.71% to -$281.8 million in 2023, then advanced by 12.89% to -$245.5 million in 2024, then gained by 10.44% to -$219.8 million in 2025, then gained by 5.66% to -$207.4 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$207.4 million in Q2 2026, -$222.8 million in Q1 2026, and -$219.8 million in Q4 2025.